CoChat
Sign Up
Cited by 26Epilepsy research and treatmentNeuroinflammation and Neurodegeneration MechanismsMicroRNA in disease regulation

Intranasal Delivery of miR-155-5p Antagomir Alleviates Acute Seizures Likely by Inhibiting Hippocampal Inflammation

Open access
Zhou, Xu, Chen, Jun, Tao, Hua, Cai, Yujie, Huang, Lidan, Zhou, Haihong, Chen, Yanyan, Cui, Lili +2 more·2020·Neuropsychiatric Disease and Treatment
DOI 10.2147/ndt.s247677PMC PMC7251485
Open this paper in CoChat — free accountOpen PDF

Abstract

INTRODUCTION: To confront the resistance to existing antiepileptic drugs, studies have gradually begun to investigate alternative pathologies distinct from the traditional treatments that overwhelmingly target ion channels. Microglia activation is the first inflammatory response in the brain, in which miR-155-5p plays a key proinflammatory role and thus represents a promising target for inflammatory modulation in epilepsy pathologies. METHODS: In this study, a pentetrazol-induced acute seizure model was established, and the seizure degree was evaluated within 60 min after pentetrazol administration. Animals were then sacrificed for hippocampal tissue collection for biological experiments. RESULTS: Intranasal delivery of miR-155-5p antagomir (30 min before pentetrazol administration) increased the percentage of animals with no induced seizures by 20%, extended the latency to generalized convulsions, and decreased seizure severity. In addition, miR-155-5p antagomir treatment alleviated hippocampal damage and decreased the expression of typical inflammatory modulators (TNF-α, IL-1β and IL-6). Further research revealed that intranasal delivery of miR-155-5p antagomir significantly decreased the relative level of miR-155-5p and increased the expression of its targets LXRα and SOCS1 in IBA1-labeled microglial cells in the hippocampus. CONCLUSION: These findings demonstrate that intranasal delivery of miR-155-5p antagomir alleviated acute seizures, likely by blocking hippocampal inflammation. However, other potential mechanisms of the effects of miR-155-5p antagomir and its long-term safety for epilepsy treatment remain to be investigated.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ndt.s247677

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Intranasal delivery of an miR-155-5p antagomir alleviated acute seizures by countering hippocampal inflammation in a pentetrazol-induced model.

    “while intranasal delivery of an miR-155-5p antagomir alleviated acute seizures by countering hippocampal inflammation in pentetrazol-induced model [62].”

    From Microglia specific deletion of miR-155 in Alzheimer’s disease mouse models reduces amyloid-β pathology but causes hyperexcitability and seizures (2023) · cites this paper as [62]

    The Results report reduced seizure severity and inflammatory markers after intranasal antagomir delivery in the pentetrazol-induced model. The Discussion and Conclusion say blocking hippocampal inflammation was the likely mechanism, whereas the citing sentence presents that causal explanation without the qualification. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 41

  1. [1]Perucca E, French J, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 2007; 6: 793– 804. doi: 10.1016/S1474-4422(07)70215-6 17706563 · DOI
  2. [2]Vezzani A, French J, Bartfai T, Baram T. The role of inflammation in epilepsy. Nat Rev Neurol. 2011; 7: 31– 40. doi: 10.1038/nrneurol.2010.178 21135885 PMC3378051 · DOI · Paper page
  3. [3]Najjar S, Bernbaum M, Lai G, Devinsky O. Immunology and epilepsy. Rev Neurol Dis. 2008; 5: 109– 116. 18838950
  4. [4]Vincent A, Irani S, Lang B. The growing recognition of immunotherapy-responsive seizure disorders with autoantibodies to specific neuronal proteins. Curr Opin Neurol. 2010; 23(2): 144– 150. doi: 10.1097/WCO.0b013e32833735fe 20164770 · DOI
  5. [5]Auvin S, Mazarati A, Shin D, Sankar R. Inflammation enhances epileptogenesis in the developing rat brain. Neurobiol Dis. 2010; 40: 303– 310. doi: 10.1016/j.nbd.2010.06.004 20600912 PMC2926147 · DOI
  6. [6]Walker L, Sills G. Inflammation and epilepsy: the foundations for a new therapeutic approach in epilepsy? Epilepsy Curr. 2012; 12: 8– 12. doi: 10.5698/1535-7511-12.1.8 22368518 PMC3280476 · DOI
  7. [7]Dubé C, Vezzani A, Behrens M, Bartfai T, Baram T. Interleukin-1beta contributes to the generation of experimental febrile seizures. Ann Neurol. 2005; 57: 152– 155. doi: 10.1002/ana.20358 15622539 PMC2909879 · DOI
  8. [8]Samland H, Huitron-Resendiz S, Masliah E, Criado J, Henriksen S, Campbell I. Profound increase in sensitivity to glutamatergic- but not cholinergic agonist-induced seizures in transgenic mice with astrocyte production of IL-6. J Neurosci Res. 2003; 73: 176– 187. doi: 10.1002/jnr.10635 12836160 · DOI
  9. [9]Akassoglou K, Probert L, Kontogeorgos G, Kollias G. Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. J Immunol. 1997; 158(1): 438– 445. 8977220
  10. [10]Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc Natl Acad Sci U S A. 1995; 92(24): 11294– 11298. doi: 10.1073/pnas.92.24.11294 7479982 PMC40618 · DOI
  11. [11]Wilcox KS, Vezzani A. Does brain inflammation mediate pathological outcomes in epilepsy? Adv Exp Med Biol. 2014; 813: 169– 183. 25012376 PMC4867105
  12. [12]Vezzani A, Balosso S, Ravizza T. The role of cytokines in the pathophysiology of epilepsy. Brain Behav Immun. 2008; 22(6): 797– 803. doi: 10.1016/j.bbi.2008.03.009 18495419 · DOI
  13. [13]De Simoni M, Perego C, Ravizza T, et al. Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. Eur J Neurosci. 2000; 12(7): 2623– 2633. doi: 10.1046/j.1460-9568.2000.00140.x 10947836 · DOI
  14. [14]Mazumder A, Sharma P, Patial V, Singh D. Ginkgo biloba L. attenuates spontaneous recurrent seizures and associated neurological conditions in lithium-pilocarpine rat model of temporal lobe epilepsy through inhibition of mammalian target of rapamycin pathway hyperactivation. J Ethnopharmacol. 2017; 204: 8– 17. 28390940
  15. [15]Riikonen R. Infantile spasms: therapy and outcome. J Child Neurol. 2004; 19: 401– 404. doi: 10.1177/088307380401900601 15446386 · DOI
  16. [16]Wirrell E, Farrell K, Whiting S. The epileptic encephalopathies of infancy and childhood. Can J Neurol Sci. 2005; 32: 409– 418. doi: 10.1017/S0317167100004388 16408569 · DOI
  17. [17]Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: a long overdue revisit. Indian Dermatol Online J. 2014; 5: 416– 425. doi: 10.4103/2229-5178.142483 25396122 PMC4228634 · DOI
  18. [18]Hanson LR, Frey WH 2nd. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008; 9(Suppl 3): S5. doi: 10.1186/1471-2202-9-S3-S5 PMC2604883 19091002 · DOI
  19. [19]Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 2004; 127: 481– 496. doi: 10.1016/j.neuroscience.2004.05.029 15262337 · DOI · Paper page
  20. [20]Lee ST, Jeon D, Chu K, et al. Inhibition of miR-203 reduces spontaneous recurrent seizures in mice. Mol Neurobiol. 2016. 27165289
  21. [21]Tao H, Zhao J, Liu T, et al. Intranasal delivery of miR-146a mimics delayed seizure onset in the lithium-pilocarpine mouse model. Mediators Inflamm. 2017; 2017: 6512620. doi: 10.1155/2017/6512620 28242958 PMC5294386 · DOI
  22. [23]Li P, Wang G, Zhang X, et al. MicroRNA-155 promotes heat stress-induced inflammation via targeting liver X Receptor α in microglia. Front Cell Neurosci. 2019; 13: 12. doi: 10.3389/fncel.2019.00012 30778287 PMC6369214 · DOI
  23. [24]Ashhab M, Omran A, Kong H, et al. Expressions of tumor necrosis factor alpha and microRNA-155 in immature rat model of status epilepticus and children with mesial temporal lobe epilepsy. J Mol Neurosci. 2013; 51: 950– 958. doi: 10.1007/s12031-013-0013-9 23636891 · DOI
  24. [25]Thorne RG, Emory CR, Ala TA, Frey WH 2nd. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res. 1995; 692: 278– 282. doi: 10.1016/0006-8993(95)00637-6 8548316 · DOI · Paper page
  25. [26]Caulder EH, Riegle MA, Godwin DW. Activation of group 2 metabotropic glutamate receptors reduces behavioral and electrographic correlates of pilocarpine induced status epilepticus. Epilepsy Res. 2014; 108: 171– 181. doi: 10.1016/j.eplepsyres.2013.10.009 24305700 PMC4378620 · DOI
  26. [27]Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol. 1972; 32: 281– 294. doi: 10.1016/0013-4694(72)90177-0 4110397 · DOI
  27. [28]Liu L, Hamre KM, Goldowitz D. Kainic acid-induced neuronal degeneration in hippocampal pyramidal neurons is driven by both intrinsic and extrinsic factors: analysis of FVB/N↔C57BL/6 chimeras. J Neurosci. 2012; 32: 12093– 12101. doi: 10.1523/JNEUROSCI.6478-11.2012 22933793 PMC6621525 · DOI
  28. [29]Djupesland PG, Messina JC, Mahmoud RA. The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Ther Deliv. 2014; 5: 709– 733. doi: 10.4155/tde.14.41 25090283 · DOI
  29. [30]Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012; 64: 614– 628. doi: 10.1016/j.addr.2011.11.002 22119441 · DOI · Paper page
  30. [31]Cai Z, Li S, Li S, et al. Antagonist targeting microRNA-155 protects against lithium-pilocarpine-induced status epilepticus in C57BL/6 mice by activating brain-derived neurotrophic factor. Front Pharmacol. 2016; 7: 129. doi: 10.3389/fphar.2016.00129 27303295 PMC4885878 · DOI
  31. [32]Cruz-Topete D, Cidlowski JA. One hormone, two actions: anti- and pro-inflammatory effects of glucocorticoids. Neuroimmunomodulation. 2015; 22: 20– 32. doi: 10.1159/000362724 25227506 PMC4243162 · DOI
  32. [33]Dinarello C. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009; 27: 519– 550. doi: 10.1146/annurev.immunol.021908.132612 19302047 · DOI · Paper page
  33. [34]Mantovani A, Locati M, Vecchi A, Sozzani S, Allavena P. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol. 2001; 22: 328– 336. doi: 10.1016/S1471-4906(01)01941-X 11377293 · DOI
  34. [36]Korotkov A, Broekaart D, van Scheppingen J, et al. Increased expression of matrix metalloproteinase 3 can be attenuated by inhibition of microRNA-155 in cultured human astrocytes. J Neuroinflammation. 2018; 15: 211. doi: 10.1186/s12974-018-1245-y 30031401 PMC6054845 · DOI · Paper page
  35. [37]Kong H, Yin F, He F, et al. The effect of miR-132, miR-146a, and miR-155 on MRP8/TLR4-induced astrocyte-related inflammation. J Mol Neurosci. 2015; 57: 28– 37. doi: 10.1007/s12031-015-0574-x 25957996 · DOI · Paper page
  36. [38]Guedes J, Custódia C, Silva R, de Almeida L, Pedroso de Lima M, Cardoso A. Early miR-155 upregulation contributes to neuroinflammation in Alzheimer’s disease triple transgenic mouse model. Hum Mol Genet. 2014; 23: 6286– 6301. 24990149
  37. [39]Yin H, Song S, Pan X. Knockdown of miR-155 protects microglia against LPS-induced inflammatory injury via targeting RACK1: a novel research for intracranial infection. J Inflammation. 2017; 14(1): 17. doi: 10.1186/s12950-017-0162-7 PMC5549339 28804270 · DOI · Paper page
  38. [40]Chen Y, Huang XJ, Yu N, et al. HMGB1 contributes to the expression of P-glycoprotein in mouse epileptic brain through toll-like receptor 4 and receptor for advanced glycation end products. PLoS One. 2015; 10. PMC4613137 26485677
  39. [41]Ji Y, Fioravanti J, Zhu W, et al. miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8 T cell fate. Nat Commun. 2019; 10: 2157. doi: 10.1038/s41467-019-09882-8 31089138 PMC6517388 · DOI
  40. [42]Wu Q, Sun S, Li Z, et al. Tumour-originated exosomal miR-155 triggers cancer-associated cachexia to promote tumour progression. Mol Cancer. 2018; 17: 155. doi: 10.1186/s12943-018-0899-5 30359265 PMC6201501 · DOI
  41. [43]Jayawardana K, Schramm S, Tembe V, et al. Identification, review, and systematic cross-validation of microRNA prognostic signatures in metastatic melanoma. J Invest Dermatol. 2016; 136(1): 245– 254. doi: 10.1038/JID.2015.355 26763444 · DOI

Cited by

Sorted by citations

Authors
Zhou, X., Chen, J., Tao, H., Cai, Y., Huang, L., Zhou, H., Chen, Y., Cui, L., Zhong, W., & Li, K.
Affiliations
  • Guangdong Medical College (CN)
  • Jinan University (CN)
Corresponding author
Tao, Hua
ORCID
Venue
Neuropsychiatric Disease and Treatment
Publisher
Informa UK Limited
Published
2020-05
Volume
Volume 16
Pages
1295-1307
ISSN
  • 1176-6328 (ISSN-L)
  • 1178-2021
DOI
10.2147/ndt.s247677
PMC
PMC7251485
OpenAlex
W3026540416
Cited by
26
References
2
Citations by year
2026: 2 · 2025: 5 · 2024: 8 · 2023: 6 · 2022: 3 · 2021: 1 · 2020: 1
FWCI
2.01
Type
journal article
Language
en
Open access
Licence
Locations
  • Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
  • Natural Science Foundation of Guangdong Province (2017A030310658)
  • Guangdong Medical Research Foundation (A2019152)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Epilepsy research and treatment
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
Keywords
miR-155-5p, antagomir, intranasal drug delivery, acute seizures, epilepsy, hippocampal inflammation, microglial activation, liver X receptor alpha, SOCS1, TNF-α, IL-1β, interleukin-6, antiepileptic drug resistance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review